These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

771 related articles for article (PubMed ID: 31550937)

  • 1. Monoclonal antibodies for the prevention of migraine.
    Raffaelli B; Neeb L; Reuter U
    Expert Opin Biol Ther; 2019 Dec; 19(12):1307-1317. PubMed ID: 31550937
    [No Abstract]   [Full Text] [Related]  

  • 2. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
    Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
    Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcitonin-gene-related peptide pathway mAbs and migraine prevention.
    Paemeleire K; MaassenVanDenBrink A
    Curr Opin Neurol; 2018 Jun; 31(3):274-280. PubMed ID: 29432219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
    Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
    Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network Meta-analysis of Randomized Controlled Trials.
    Yang CP; Zeng BY; Chang CM; Shih PH; Yang CC; Tseng PT; Wang SJ
    Neurotherapeutics; 2021 Oct; 18(4):2639-2650. PubMed ID: 34580838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention.
    Caronna E; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
    Handb Clin Neurol; 2024; 199():107-124. PubMed ID: 38307640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.
    Tringali G; Navarra P
    Peptides; 2019 Jun; 116():16-21. PubMed ID: 31018157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Migraine therapeutics differentially modulate the CGRP pathway.
    Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
    Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
    Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
    CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?
    Nagaraj K; Vandenbussche N; Goadsby PJ
    Neurol India; 2021; 69(Supplement):S59-S66. PubMed ID: 34003149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis.
    Soni P; Chawla E
    Clin Neurol Neurosurg; 2021 Oct; 209():106893. PubMed ID: 34464833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC; Schwedt TJ
    Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
    Zhu Y; Liu Y; Zhao J; Han Q; Liu L; Shen X
    Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive overview and safety evaluation of fremanezumab as a preventive therapy for migraine.
    Parikh SK; Burkett JG; Silberstein SD
    Expert Opin Drug Saf; 2020 May; 19(5):537-543. PubMed ID: 32116061
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
    Yuan H; Spare NM; Silberstein SD
    Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.
    Alex A; Vaughn C; Rayhill M
    Headache; 2020 Nov; 60(10):2454-2462. PubMed ID: 32969035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies.
    Mitsikostas DD; Reuter U
    Curr Opin Neurol; 2017 Jun; 30(3):272-280. PubMed ID: 28240610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies as a preventive therapy for migraine: A meta-analysis.
    Alasad YW; Asha MZ
    Clin Neurol Neurosurg; 2020 Aug; 195():105900. PubMed ID: 32460120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.